Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- RNAi-Pathway Components and Mechanisms
-
1. Activation of gene expression by double-stranded RNAs
- Prof. Long-Cheng Li
-
2. MicroRNA biogenesis
- Dr. Narry Kim
-
3. Dicer and R2D2
- Dr. Young Sik Lee
-
4. Mammalian microRNA assembly and function
- Prof. Zissimos Mourelatos
-
5. Mechanisms of RNAi: a molecular view or Argonaute: the secret life of Slicer
- Prof. Leemor Joshua-Tor
- Roles for RNAi in Development and Anti-Viral Defense
-
6. Functional roles of RNAi in C. elegans
- Dr. Eric Miska
-
7. RNAi and heterochromatin in plants and fission yeast
- Prof. Robert Martienssen
-
8. RNA interference functions and mechanisms in animals
- Prof. Richard Carthew
-
9. Specific functional roles in mammals
- Dr. Michael McManus
- RNAi Design Rules for Applications in Humans
-
10. siRNA on and off-target
- Prof. Anastasia Khvorova
-
11. Cell signalling pathways and RNAi
- Mr. Michael O'Grady
-
12. RNAi: key technological aspects
- Dr. Dmitry Samarsky
- Dr. Ciaran Faherty
-
13. RNAi specificity: how big of an issue is it?
- Dr. Peter Welch
- Applications of RNAi in the Treatment of Human Diseases
-
14. siRNA therapeutics
- Prof. John Rossi
- Mr. Daniel J. Rossi
-
15. RNAi for neurological diseases
- Prof. Beverly L. Davidson
-
16. RNA interference and cancer: a revolution?
- Dr. Annick Harel-Bellan
- Archived Lectures *These may not cover the latest advances in the field
-
17. RNAi and viral heart infections
- Dr. Jens Kurreck
-
18. RNA interference for neurodegenerative diseases
- Prof. Beverly L. Davidson
-
19. Activation of gene expression by double-stranded RNA
- Prof. David Corey
-
20. New designs for siRNAs as Dicer substrate
- Dr. Mark Behlke
-
21. RNAi in the model system Drosophila
- Prof. Richard Carthew
-
23. Therapeutic delivery of RNAi
- Dr. Patrick Lu
-
24. Mechanistic aspects and therapeutic applications of RNAi
- Prof. John Rossi
Printable Handouts
Navigable Slide Index
- Introduction
- RNAi therapeutic development
- RNAi cellular activity
- In vivo siRNA delivery is the key
- Clinically-viable siRNA deliveries
- Intra-tumoral siRNA delivery
- Gene silencing in tumor
- Raf-1 siRNA inhibits tumor growth
- siRNA-mediated validation in vivo
- Cancer target validation
- RNAi effect in mouse brain
- RNAi effects in mouse CIA model
- Ocular siRNA delivery subconjunctival
- Ocular siRNA delivery: intravitreus
- Intra-tracheal siRNA delivery
- Primate study design
- Relief from SCV-induced fever
- Minimized lung damages
- Protect monkey lung from infection
- Challenges to siRNA systemic delivery
- Systemic delivery technology
- Targeted nanoparticle siRNA delivery
- Self assembled nanoparticle
- Integrin alfa-v-beta-3 is validated target
- Dual-targeted therapeutic approach
- Neovasculature targeting siRNA
- Multi-targeted anti-angiogenesis
- Systemic siRNA delivery to eyes
- Efficient targeted systemic delivery
- Neuroblastoma treatment
- Tumor neovasculature inhibition
- siRNA/atelocollagen anti-tumor efficacy
- Transferrin-mediated systemic delivery
- Antibody-mediated tumor targeting
- Targeted anti-HBV activity
- RNAi effect of chol-siRNA
- PEI-mediated siRNA lung targeting
- Conclusion: therapeutic delivery
Topics Covered
- RNAi therapeutics development
- RNAi cellular activity
- In vivo siRNA delivery is key
- Clinically viable siRNA deliveries
- Local delivery of siRNA
- Gene silencing in tumors
- Cancer target validation in vivo
- RNAi effects in mouse brain, joints, eyes and lungs
- siRNA therapeutics in primate models
- Challenges to siRNA systemic delivery
- Systemic delivery technology
- Targeted nanoparticle siRNA delivery
- Self assembled nanoparticle
- Integrin av-beta is a validated target
- Dual-targeted therapeutic approach
- Neovasculature targeting siRNA
- Multi-targeted anti-angiogenesis
- Efficient targeted systemic delivery
- Systemic siRNA delivery to eyes
- Systemic siRNA delivery for neuroblastoma treatment
- Tumor neovasculature inhibition
- siRNA/Atelocollagen anti-tumor efficacy
- Transferrin-mediated systemic delivery
- Antibody-mediated tumor targeting
- Targeted anti-HBV activity
- RNAi effect of chol-siRNA
- PEI-mediated siRNA lung targeting
- Clinicallyviable delivery is the key for successful siRNA therapeutics
Links
Series:
Categories:
Talk Citation
Lu, P. (2007, October 1). Therapeutic delivery of RNAi [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 25, 2024, from https://hstalks.com/bs/657/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Patrick Lu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.